18 Sep 2017

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

Mereo BioPharma to Present at Cantor Global Healthcare Conference on 26 September 2017 

London, 18 September 2017 – Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, is pleased to announce that Denise Scots-Knight, Chief Executive Officer of Mereo will present an overview of the business at the Cantor Global Healthcare Conference 2017, to be held 25-27 September 2017 in New York.

Mereo BioPharma Presentation Details

Date: Tuesday, 26 September 2017

Time: 8:35-9:05 AM ET (1:35-2.05 PM BST)

Location: InterContinental New York Barclay Hotel, 111 E 48th St, New York, NY 10017, USA

Track & Room: Grand Ballroom 2 - Track 5

FOR FURTHER ENQUIRIES:

Mereo BioPharma Group plc
+44 (0)333 023 7319
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer

Nominated Adviser and Joint Broker
Cantor Fitzgerald Europe

+44 (0)20 7894 7000
Phil Davies
Will Goode

Joint Broker
RBC Capital Markets

+44 (0)20 7653 4000
Rupert Walford
Laura White

UK Public Relations Advisor to Mereo Biopharma
FTI Consulting

+44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard

US Public Relations Advisor to Mereo Biopharma
Burns McClellan

+01 (0) 212 213 0006
Lisa Burns
Steven Klass

ABOUT MEREO

Mereo BioPharma is an innovative biopharma company established to address the development and financial challenges faced by an increasing number of large pharma and biotech companies. Mereo focuses on developing and optimising the value of novel medicines acquired from large pharma and biotech designed to address significant unmet medical needs in rare and specialty disease areas.

Mereo is comprised of a strong team with broad operational capabilities and the financial resources to conduct comprehensive clinical studies. The Company plans to build a rare and orphan commercial business combined with plans to partner products where appropriate.

Mereo's initial portfolio consists of three mid-late stage clinical assets that were acquired from Novartis in July 2015 each with proof of concept data in the indication that Mereo is now developing.  BPS-804 is being developed for the treatment of osteogenesis imperfecta (brittle bone disease); acumapimod (BCT-197), is being developed to treat inflammation in patients with an AECOPD; and BGS-649 is a once-weekly oral novel therapy that restores the patient's own testosterone in men with hypogonadotropic hypogonadism. In H1 2016 the Company initiated a Phase 2 study with acumapimod and a Phase 2b study with BGS-649. Mereo recently announced commencement of the first potentially pivotal trial for BPS-804 and completion of enrolment of the acumapimod Phase 2 study. Additional product opportunities, from a range of large pharmaceutical and biotechnology companies, are under active evaluation and these are focussed on orphan and rare diseases.

download PDF​